Company overview
Biodesix provides advanced blood-based diagnostic tests for lung cancer risk assessment and treatment guidance, including Nodify Lung, GeneStrat, and VeriStrat tests. They offer custom development services to biopharmaceutical and life sciences companies for therapeutic clinical trials, diagnostic validation, and commercialization of IVD and LDT tests. Their AI and machine learning capabilities support personalized care and early lung cancer detection.
Biodesix is listed in the NovaPharmaNews Supplier Hub as a Diagnostics & Testing partner serving United States & Americas. Core focus areas include lung cancer diagnostics, blood-based tests, nodify lung, genestrat, diagnostic development services.
Industry categories: Diagnostics & Testing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Products and technologies associated with Biodesix include Diagnostic — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://www.biodesix.com
- Categories
- Diagnostics & Testing
- Markets served
- United States & Americas
- Keywords
- lung cancer diagnostics, blood-based tests, nodify lung, genestrat, diagnostic development services
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What diagnostic tests does Biodesix offer for lung cancer?
- Biodesix offers Nodify Lung for pulmonary nodule risk assessment, GeneStrat and GeneStrat NGS for tumor mutation testing in NSCLC, and VeriStrat for immunotherapy guidance.
- What development services are available for pharma and life sciences?
- Biodesix provides custom services to enable therapeutic clinical trials, validate diagnostics and life sciences tools, and develop/commercialize novel diagnostics, including specimen kitting and high-throughput molecular testing.
- What regulatory validations has Biodesix achieved?
- Biodesix validated Thermo Fisher's Oncomine Dx Express Test for solid tumors on the Genexus Dx Integrated Sequencer, contributing to its FDA approval.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
